CYNO Cynosure - Class A (MM)

Device to Debut at American Academy of Dermatology Meeting WESTFORD, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the addition of a new 1320 nm wavelength Nd:YAG laser for its flagship Affirm(TM) workstation, one of the industry's most comprehensive solutions for anti-aging applications, including skin rejuvenation, treatments for wrinkles, discoloration and now tissue tightening as a result of tissue coagulation. The new laser, which is emitted through a proprietary disposable micro-lens array, will be debuted at the American Academy of Dermatology's 2007 Annual Meeting, which begins today in Washington, D.C. "We are excited about the addition of the 1320 nm Nd:YAG laser for deep heating, which completes our platform Affirm workstation for anti-aging applications. The Affirm now incorporates three energy sources and provides a versatile, flexible and cost-effective product for our customers," said Cynosure President and CEO Michael Davin. "The Affirm now can deliver a deep- heating component for tissue tightening as a result of tissue coagulation, which complements the current 1440 nm Nd:YAG laser for fractional micro-rejuvenation and the Xenon Pulsed Light system for discoloration." The Affirm is the only anti-aging system to couple Cynosure's proprietary Combined Apex Pulse(TM) (CAP) and Mulitplex(TM) technology in one device. The CAP technology is a unique, high-density disposable lens array that redistributes laser energy in a combination of high and low level heat to stimulate and remodel collagen production throughout the treatment area. The system utilizes Cynosure's patent pending Multiplex technology to enable the rapid sequential emission of two wavelengths, 1320 nm and 1440 nm, from the same optical fiber with a short delay between fixed pulses. According to the Millennium Research Group, the skin rejuvenation market is expected to grow annually by 18 percent, resulting in a $239 million industry by 2010, with approximately 4.4 million procedures performed per year by 2010. Davin commented, "Prior to Affirm, physicians could only target one condition and one skin layer during each treatment. With Affirm they can now target multiple layers and treat fine to moderate wrinkles, solar damage and skin laxity during a single session that can last as little as 15 minutes. Previously, patients often faced longer, more painful procedures that penetrated into the dermal layers and could damage potentially healthy skin. With Affirm and the integrated SmartCool(TM) system, the energy is delivered to the optimal treatment depth, with less pain." "We've found that treatments using the Affirm are often short enough that patients can come in for treatment on their lunch breaks," said Bruce E. Katz, M.D., Director, Juva Skin & Laser Center. "In our experience, the Affirm system is effective in the treatment of wrinkles and scars, and tightens the overlying tissue. We are pleased not only with the results, but with the ease of treatment, especially because there are no messy gels or topical anesthetics needed." About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com/. Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the future use and market acceptance of the Affirm system, the markets in which Cynosure's products are sold, and other statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our history of operating losses, our reliance on sole source suppliers, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's Annual Report on Form 10-K filed with the SEC. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. DATASOURCE: Cynosure, Inc. CONTACT: Scott Solomon, Vice President of Sharon Merrill Associates, Inc., +1-617-542-5300, ; or Gretchen Bender of Greenough Communications, Web site: http://www.cynosurelaser.com/

Copyright